Retatrutide is not yet approved by the FDA. That means no official retail price exists right now. But based on how similar drugs are priced, and what Eli Lilly has done with tirzepatide, we can make a solid estimate of what you will likely pay out of pocket.
The short answer is this: expect to pay somewhere between $800 and $1,500 per month without insurance, once retatrutide hits the market. That range is based on current GLP-1 drug pricing patterns and the fact that retatrutide is a triple agonist, meaning it targets three hormone receptors instead of two. More complexity usually means higher cost.
What Is Retatrutide and Why Does It Cost More?
Retatrutide targets GIP, GLP-1, and glucagon receptors all at once. Tirzepatide, which is already approved and sold as Mounjaro and Zepbound, hits two of those. Semaglutide hits one. The more receptors a drug targets, the more complex it is to manufacture, and that cost gets passed to you.
In phase 2 clinical trials published in the New England Journal of Medicine in 2023, participants on the highest dose of retatrutide lost an average of 24.2% of their body weight over 48 weeks. That is more than any approved weight-loss drug has shown in trials. Eli Lilly knows this. They will price it accordingly.
How Much Does Retatrutide Cost Without Insurance Right Now?
Right now, you cannot buy FDA-approved retatrutide at any price. It is still in phase 3 trials. Some compounding pharmacies claim to offer it, but the FDA has not approved any compounded version of retatrutide. Buying from those sources carries real risk, including unknown purity and dosing.
Once approved, here is what the pricing landscape looks like based on comparable drugs:
- Semaglutide (Wegovy) without insurance runs $1,300 to $1,600 per month in the US
- Tirzepatide (Zepbound) without insurance runs $1,000 to $1,300 per month in the US
- Retatrutide, as a next-generation triple agonist, will likely land at $1,200 to $1,800 per month at launch
In Australia, the UK, and Canada, prices tend to be lower due to government drug pricing controls. Wegovy in Australia, for example, costs around $400 to $500 AUD per month. Retatrutide will likely follow a similar pattern in those markets once approved there.
Is Retatrutide Available to Buy Without a Prescription?
No. Retatrutide will require a prescription in every market it enters. It is a Schedule IV controlled substance class of drug in terms of how it will be regulated, similar to other injectable weight-loss medications. You will need a doctor to prescribe it.
What I have seen with tirzepatide and semaglutide is that telehealth platforms made access much easier once those drugs were approved. The same will happen with retatrutide. You will be able to get a prescription through an online consultation without needing to visit a clinic in person. That lowers the barrier significantly.
Will Insurance Cover Retatrutide When It Is Approved?
Maybe, but do not count on it at launch. Here is the pattern with every major weight-loss drug so far:
- Drug gets FDA approval
- Insurance companies classify it as a lifestyle drug and deny coverage
- Manufacturers push for coverage through employer health plans
- Coverage slowly expands over 2 to 4 years
Wegovy was approved in 2021. As of 2024, only about 25% of commercial insurance plans cover it, according to KFF Health News. Medicare Part D still does not cover weight-loss drugs as a standard benefit, though the Treat and Reduce Obesity Act has been pushing to change that.
Retatrutide will face the same fight. If you have type 2 diabetes, your odds of coverage go up because GLP-1 drugs are more commonly covered for metabolic disease than for weight loss alone. Without a diabetes diagnosis, you are likely paying out of pocket for the first few years.
How Does Retatrutide Compare in Cost to Other Weight-Loss Drugs?
Here is a direct comparison of what you are looking at across the main options:
- Orlistat (Xenical/Alli) costs $30 to $100 per month. It blocks fat absorption. Average weight loss is 3 to 5% of body weight. Cheap but weak.
- Phentermine-topiramate (Qsymia) costs $100 to $200 per month. Average weight loss is 8 to 10%. Oral pill, easier to take.
- Semaglutide (Wegovy) costs $1,300 to $1,600 per month without insurance. Average weight loss is 15% of body weight over 68 weeks, based on the STEP 1 trial.
- Tirzepatide (Zepbound) costs $1,000 to $1,300 per month without insurance. Average weight loss is 20.9% over 72 weeks, based on the SURMOUNT-1 trial.
- Retatrutide is projected at $1,200 to $1,800 per month. Average weight loss in phase 2 was 24.2% over 48 weeks.
The cost per kilogram of fat lost actually favors retatrutide if the phase 3 data holds up. You pay more per month but you lose more weight faster. In my experience looking at the data, the drugs that produce the most dramatic results tend to justify their price for people who have struggled with obesity long-term.
Are There Patient Assistance Programs for Retatrutide?
Not yet, because the drug is not approved. But Eli Lilly already runs assistance programs for tirzepatide. The Lilly Cares Foundation offers Mounjaro for free or reduced cost to people who qualify based on income. Once retatrutide is approved, expect a similar program to launch within 6 to 12 months.
What I found with tirzepatide is that the savings card programs at launch were aggressive. Eli Lilly offered tirzepatide for $25 per month for the first year through their savings card for commercially insured patients. They will likely do the same with retatrutide to drive adoption.
For people without insurance, the path to affordability usually looks like this:
- Manufacturer savings card at launch, often $25 to $100 per month for eligible patients
- Income-based patient assistance programs through the manufacturer
- GoodRx or similar discount programs once the drug has been on the market for 6 to 12 months
- Compounded versions through licensed pharmacies if the FDA allows it, which happened with semaglutide during the shortage
When Will Retatrutide Be Available to the Public?
Eli Lilly is currently running phase 3 trials. Based on the timeline, the earliest realistic FDA approval date is late 2025 or 2026. Phase 3 trials for obesity drugs typically run 72 to 96 weeks, and the FDA review process adds another 6 to 12 months after submission.
For international markets like Australia, the UK, and Canada, add another 12 to 24 months after US approval. The TGA in Australia and MHRA in the UK run their own review processes. Wegovy was approved in the US in 2021 and did not reach Australia until 2023.
The realistic timeline for most people outside the US is 2027 at the earliest for approved access.
Three Things Most People Get Wrong About Retatrutide Costs
First, people assume compounded retatrutide is a safe workaround. It is not. The FDA has not approved any compounded version, and the raw peptide being sold by some online pharmacies has not been tested for human use at clinical doses. What I saw with compounded semaglutide is that some batches had serious dosing errors. The risk is real.
Second, people assume the sticker price is what they will pay. Manufacturer savings programs, employer health benefits, and HSA or FSA accounts can all reduce the real cost. A $1,500 drug can become a $200 drug with the right combination of programs.
Third, people compare the monthly cost without comparing the outcome. Spending $1,500 per month on a drug that produces 24% weight loss is a different calculation than spending $100 per month on a drug that produces 5% weight loss. The cost per unit of outcome matters more than the monthly price.
FAQ
How much is retatrutide without insurance in the US?
No official price exists yet. Based on comparable drugs, expect $1,200 to $1,800 per month at launch without insurance or manufacturer discounts.
Can I buy retatrutide online right now?
No legitimate source sells FDA-approved retatrutide because it has not been approved yet. Any site claiming to sell it is selling an unapproved compound with unknown safety.
Will Medicare cover retatrutide?
Medicare does not currently cover weight-loss drugs as a standard benefit. That may change with pending legislation, but at launch, Medicare patients will likely pay out of pocket.
Is retatrutide stronger than Ozempic?
Yes, based on trial data. Retatrutide produced 24.2% average weight loss in phase 2 trials. Semaglutide (the active ingredient in Ozempic and Wegovy) produced 15% in its pivotal trials. Retatrutide targets three hormone receptors versus one for semaglutide.
How does retatrutide cost compare to tirzepatide?
Tirzepatide currently costs $1,000 to $1,300 per month without insurance. Retatrutide will likely cost slightly more at launch given its added complexity, but manufacturer savings programs could bring both to similar out-of-pocket costs for eligible patients.
What is the cheapest way to get retatrutide when it is approved?
The cheapest path will be through the manufacturer’s savings card program at launch, combined with an HSA or FSA account to pay with pre-tax dollars. For low-income patients, the Lilly Cares Foundation or equivalent program will likely offer free or reduced-cost access.
What This Means for Your Weight Loss Plan Right Now
Retatrutide is not available yet, and the cost without insurance will be significant when it does arrive. The people who get the best results with any of these drugs are the ones who combine medication with real changes to their training and nutrition. The drug reduces appetite and improves metabolic function, but it does not build muscle or teach you how to eat.
Working with an online personal trainer while using a GLP-1 drug is one of the most effective combinations I have seen. The drug handles the hunger side. The coach handles the strength, the habits, and the long-term structure. That combination produces results that last beyond the medication cycle.
If you are waiting for retatrutide to be approved, the time between now and then is not wasted time. Building a solid training foundation now means you are ready to maximize the drug’s effects when it becomes available. The people who start from zero when the drug arrives get far less out of it than the people who already have a training base.
